Market Research Logo

Diabetic Macular Edema - Pipeline Review, H1 2015

Diabetic Macular Edema - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Diabetic Macular Edema - Pipeline Review, H1 2015’, provides an overview of the Diabetic Macular Edema’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diabetic Macular Edema and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diabetic Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Diabetic Macular Edema Overview
Therapeutics Development
Pipeline Products for Diabetic Macular Edema - Overview
Pipeline Products for Diabetic Macular Edema - Comparative Analysis
Diabetic Macular Edema - Therapeutics under Development by Companies
Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes
Diabetic Macular Edema - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Diabetic Macular Edema - Products under Development by Companies
Diabetic Macular Edema - Products under Investigation by Universities/Institutes
Diabetic Macular Edema - Companies Involved in Therapeutics Development
ActiveSite Pharmaceuticals, Inc.
Acucela Inc.
Aerpio Therapeutics, Inc.
Alcon, Inc.
Allergan, Inc.
AlphaMab Co., Ltd
Ampio Pharmaceuticals, Inc.
Astellas Pharma Inc.
Auven Therapeutics Management L.L.L.P
Avalanche Biotechnologies, Inc.
Eleven Biotherapeutics Inc.
F. Hoffmann-La Roche Ltd.
Foamix Pharmaceuticals Ltd.
Gene Signal International SA
Genmab A/S
GlaxoSmithKline plc
Icon Bioscience, Inc.
Kala Pharmaceuticals, Inc.
Kowa Company, Ltd.
Mabion SA
MacuCLEAR, Inc.
Molecular Design International, Inc.
NicOx S.A.
Ohr Pharmaceutical Inc.
Pfizer Inc.
Quark Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
SciFluor Life Sciences, LLC
Senju Pharmaceutical Co., Ltd.
ThromboGenics NV
Diabetic Macular Edema - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
49-B - Drug Profile
abicipar pegol - Drug Profile
aganirsen - Drug Profile
AKB-9778 - Drug Profile
ALG-1001 - Drug Profile
Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile
ASP-440 - Drug Profile
ASP-8232 - Drug Profile
AVA-101 - Drug Profile
conbercept - Drug Profile
danazol - Drug Profile
darapladib - Drug Profile
dexamethasone acetate nanoparticle - Drug Profile
dexamethasone dipropionate - Drug Profile
difluprednate - Drug Profile
Drug for Diabetic Macular Edema - Drug Profile
Drugs to Inhibit Tyrosine Kinase for Ophthalmology - Drug Profile
EBI-029 - Drug Profile
EBI-031 - Drug Profile
emixustat hydrochloride - Drug Profile
KVD-001 - Drug Profile
LKA-651 - Drug Profile
loteprednol etabonate - Drug Profile
MC-4001 - Drug Profile
minocycline Gel - Drug Profile
MTP-131 - Drug Profile
NCX-422 - Drug Profile
NCX-434 - Drug Profile
nesvacumab - Drug Profile
ocriplasmin (recombinant) - Drug Profile
Peptide for Diabetic Macular Edema - Drug Profile
PF-04634817 - Drug Profile
PF-655 - Drug Profile
ranibizumab - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
ripasudil - Drug Profile
RX-10045 - Drug Profile
SF-0166 - Drug Profile
Small Molecule to Inhibit Kallikrein for AMD and DME - Drug Profile
Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile
Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema - Drug Profile
squalamine lactate - Drug Profile
teprotumumab - Drug Profile
Diabetic Macular Edema - Recent Pipeline Updates
Diabetic Macular Edema - Dormant Projects
Diabetic Macular Edema - Discontinued Products
Diabetic Macular Edema - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diabetic Macular Edema, H1 2015
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Acucela Inc., H1 2015
Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Alcon, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Allergan, Inc., H1 2015
Diabetic Macular Edema - Pipeline by AlphaMab Co., Ltd, H1 2015
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H1 2015
Diabetic Macular Edema - Pipeline by Auven Therapeutics Management L.L.L.P, H1 2015
Diabetic Macular Edema - Pipeline by Avalanche Biotechnologies, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Eleven Biotherapeutics Inc., H1 2015
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Diabetic Macular Edema - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015
Diabetic Macular Edema - Pipeline by Gene Signal International SA, H1 2015
Diabetic Macular Edema - Pipeline by Genmab A/S, H1 2015
Diabetic Macular Edema - Pipeline by GlaxoSmithKline plc, H1 2015
Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H1 2015
Diabetic Macular Edema - Pipeline by Mabion SA, H1 2015
Diabetic Macular Edema - Pipeline by MacuCLEAR, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Molecular Design International, Inc., H1 2015
Diabetic Macular Edema - Pipeline by NicOx S.A., H1 2015
Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H1 2015
Diabetic Macular Edema - Pipeline by Pfizer Inc., H1 2015
Diabetic Macular Edema - Pipeline by Quark Pharmaceuticals, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015
Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015
Diabetic Macular Edema - Pipeline by SciFluor Life Sciences, LLC, H1 2015
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2015
Diabetic Macular Edema - Pipeline by ThromboGenics NV, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Diabetic Macular Edema Therapeutics - Recent Pipeline Updates, H1 2015
Diabetic Macular Edema - Dormant Projects, H1 2015
Diabetic Macular Edema - Dormant Projects (Contd..1), H1 2015
Diabetic Macular Edema - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Diabetic Macular Edema, H1 2015
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report